Sunny Pharmtech announced on the 30th that its multi-cancer drug CPA-I, launched in the U.S. in December last year, has seen smooth sales, quickly becoming the company's second-largest revenue driver within six months. In the first half of the year, CPA-I accounted for 15% of total revenue, second only to the anti-infective drug NFT.
Sunny Pharmtech noted that due to ongoing additional orders from its U.S. sales partner, the production capacity is insufficient to meet the demand. The company has applied to the U.S. FDA to upgrade its production line from semi-automatic to fully automatic. Approval is expected by the end of this year, which would potentially double the production capacity and help reduce production costs. Based on current market demand, CPA-I could become the company's top revenue contributor next year, significantly boosting overall performance.
In the first half of this year, Sunny Pharmtech's consolidated revenue reached NT$233 million, an annual increase of 31.68%. This growth was driven by increased demand for its drugs, sales growth, profit sharing, and new CDMO projects.
Chairman Yon-Lian Wu stated that Sunny Pharmtech targets the U.S. market, which has stringent regulatory standards, as its primary market. From the early stages of product development, the company adopted a dual strategy of "sales profit sharing" and "licensing profit sharing," with drug certification ownership based on mutual agreements. Of the seven niche products currently on the U.S. market, Sunny Pharmtech holds five drug certifications, including the anti-infective drug NFT-C, gynecological drug CPT-I, hemostatic agents AMT-T and AMA-S, and the multi-cancer drug CPA-I. These were all independently developed by Sunny Pharmtech and licensed to local partners for sale, generating sales revenue and profit-sharing income.
For the other two listed products (local short-acting anesthetic LDC-O and anemia drug CYA-I), the drug certifications are held by partners. Although Sunny Pharmtech does not supply these products, it receives profit-sharing income.
Yon-Lian Wu further explained that both "sales profit sharing" and "licensing profit sharing" are evaluated based on the topic, mutual strengths, and market demand to achieve a win-win situation and capture market share in the world's largest pharmaceutical market. According to IQVIA, in the fourth quarter of last year, Sunny Pharmtech's hemostatic agent AMA-T and anti-infective drug NFT-C held market shares of 13% and 12%, respectively, in the U.S. The gynecological drug CPT-I also had about a 7% market share, while the newly launched multi-cancer drug CPA-I was in high demand, with potential for substantial market share.
According to IQVIA data, drugs with the same active ingredient as CPA-I had total U.S. sales of about $100 million in the past year. Currently, there are no original drugs being sold, only five alternative generic drugs. CPA-I, developed and produced entirely in-house from raw material to finished product by Sunny Pharmtech, offers high-quality raw material assurance and cost competitiveness. Coupled with the strong distribution network of its local partner, it is expected that after the production line upgrade and capacity doubling, CPA-I will further increase its market share and become a major growth driver for Sunny Pharmtech's performance.
Resource (mandarin): 祥翊多重抗癌用藥CPA-I供不應求 產線優化明年產能翻倍
